S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
S&P 500   3,750.77 (-2.57%)
DOW   30,303.17 (-2.05%)
QQQ   319.43 (-2.79%)
AAPL   142.06 (-0.77%)
MSFT   232.90 (+0.25%)
FB   272.14 (-3.51%)
GOOGL   1,818.94 (-4.67%)
AMZN   3,232.58 (-2.81%)
TSLA   864.16 (-2.14%)
NVDA   516.71 (-3.85%)
BABA   260.25 (-2.13%)
CGC   37.83 (+6.50%)
GE   11.38 (+0.80%)
MU   75.09 (-5.56%)
AMD   88.84 (-6.20%)
NIO   57.15 (-5.24%)
T   29.14 (-2.05%)
F   10.79 (-3.57%)
ACB   11.20 (+4.97%)
BA   194.03 (-3.97%)
DIS   163.03 (-3.85%)
NFLX   523.28 (-6.88%)
GILD   65.48 (-1.83%)
Log in
NASDAQ:DVAX

Dynavax Technologies Stock Forecast, Price & News

$6.14
-0.03 (-0.49 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.88
Now: $6.14▼
$6.73
50-Day Range
$4.45
MA: $5.00▼
$6.55
52-Week Range
$1.80
Now: $6.14▼
$12.44
Volume5.08 million shs
Average Volume3.25 million shs
Market Capitalization$676.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.
Dynavax Technologies logo

MarketRank™

Overall MarketRank™

1.66 out of 5 stars

Medical Sector

250th out of 1,926 stocks

Pharmaceutical Preparations Industry

125th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:DVAX
Previous Symbol
CUSIP26815810
CIK1029142
Webwww.dynavax.com
Phone510-848-5100
Employees231
Year FoundedN/A

Debt

Debt-to-Equity Ratio2.59
Current Ratio4.35
Quick Ratio3.47

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.22 million
Price / Sales19.21
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.10 per share
Price / Book61.40

Profitability

EPS (Most Recent Fiscal Year)($1.87)
Net Income$-152,600,000.00
Net Margins-256.92%
Return on Equity-193.85%
Return on Assets-23.45%

Miscellaneous

Outstanding Shares110,173,000
Market Cap$676.46 million
Next Earnings Date3/10/2021 (Estimated)
OptionableOptionable
$6.14
-0.03 (-0.49 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

How has Dynavax Technologies' stock price been impacted by COVID-19 (Coronavirus)?

Dynavax Technologies' stock was trading at $3.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DVAX stock has increased by 102.0% and is now trading at $6.20.
View which stocks have been most impacted by COVID-19.

Is Dynavax Technologies a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dynavax Technologies stock.
View analyst ratings for Dynavax Technologies or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Dynavax Technologies?

Wall Street analysts have given Dynavax Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dynavax Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies CEO Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among Dynavax Technologies' employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Dynavax Technologies.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) announced its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05. The biopharmaceutical company earned $13.41 million during the quarter, compared to the consensus estimate of $11.01 million. Dynavax Technologies had a negative trailing twelve-month return on equity of 193.85% and a negative net margin of 256.92%.
View Dynavax Technologies' earnings history.

What price target have analysts set for DVAX?

4 brokers have issued 12 month price objectives for Dynavax Technologies' shares. Their forecasts range from $14.00 to $20.00. On average, they anticipate Dynavax Technologies' share price to reach $16.00 in the next year. This suggests a possible upside of 158.1% from the stock's current price.
View analysts' price targets for Dynavax Technologies or view Wall Street analyst' top-rated stocks.

Who are some of Dynavax Technologies' key competitors?

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Ionis Pharmaceuticals (IONS) and Novavax (NVAX).
View all of DVAX's competitors.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the following people:
  • Mr. Ryan Spencer, CEO & Director (Age 43, Pay $545.59k)
  • Mr. David F. Novack, Pres & COO (Age 59, Pay $697.27k)
  • Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 69, Pay $662.54k)
  • Dr. Robert Janssen, Chief Medical Officer & Sr. VP of Clinical Devel., Medical and Regulatory Affairs (Age 67, Pay $666.13k)
  • Mr. Justin Burgess, Principal Accounting Officer & Controller
  • Ms. Heather Rowe, VP of Investor Relations & Corp. Communications
  • Mr. Steven N. Gersten, Chief Ethics & Compliance Officer, Sr. VP, Gen. Counsel and Sec.
  • Mr. Donn Casale, VP of Sales & Marketing
  • Ms. Cecilia Vitug, VP of HR
  • Mr. Jeff P. Coon, Sr. VP of HR & Corp. Services (Age 58)

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Chicago Capital LLC (5.25%), Pacer Advisors Inc. (0.02%), Kestra Advisory Services LLC (0.02%) and Perennial Investment Advisors LLC (0.01%). Company insiders that own Dynavax Technologies stock include Andrew A F Hack, David Louis Johnson, Francis Cano, Michael S Ostrach, Robert Coffman and Robert Janssen.
View institutional ownership trends for Dynavax Technologies.

Which major investors are buying Dynavax Technologies stock?

DVAX stock was bought by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Pacer Advisors Inc., Perennial Investment Advisors LLC, and Kestra Advisory Services LLC. Company insiders that have bought Dynavax Technologies stock in the last two years include Andrew A F Hack, and Francis Cano.
View insider buying and selling activity for Dynavax Technologies or or view top insider-buying stocks.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $6.20.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $683.07 million and generates $35.22 million in revenue each year. The biopharmaceutical company earns $-152,600,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Dynavax Technologies employs 231 workers across the globe.

What is Dynavax Technologies' official website?

The official website for Dynavax Technologies is www.dynavax.com.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.